Works by Snorgaard, Ole


Results: 9
    1
    2

    Effects of DPP‐4 inhibitors, GLP‐1 receptor agonists, SGLT‐2 inhibitors and sulphonylureas on mortality, cardiovascular and renal outcomes in type 2 diabetes: A network meta‐analyses‐driven approach.

    Published in:
    Diabetic Medicine, 2023, v. 40, n. 8, p. 1, doi. 10.1111/dme.15157
    By:
    • Brønden, Andreas;
    • Christensen, Mikkel Bring;
    • Glintborg, Dorte;
    • Snorgaard, Ole;
    • Kofoed‐Enevoldsen, Allan;
    • Madsen, Gitte Krogh;
    • Toft, Katja;
    • Kristensen, Jette Kolding;
    • Højlund, Kurt;
    • Hansen, Troels Krarup;
    • Søndergaard, Esben;
    • Hansen, Katrine Bagge
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9

    Study rationale and design of the EANITIATE study (EmpAgliflozin compared to NPH Insulin for sTeroId diAbeTEs) - a randomized, controlled, multicenter trial of safety and efficacy of treatment with empagliflozin compared with NPH-insulin in patients with newly onset diabetes following initiation of glucocorticoid treatment

    Published in:
    BMC Endocrine Disorders, 2020, v. 20, n. 1, p. 1, doi. 10.1186/s12902-020-00561-0
    By:
    • Klarskov, Carina Kirstine;
    • Holm Schultz, Helga;
    • Persson, Frederik;
    • Møller Christensen, Tomas;
    • Almdal, Thomas Peter;
    • Snorgaard, Ole;
    • Bagge Hansen, Katrine;
    • Pedersen-Bjergaard, Ulrik;
    • Lommer Kristensen, Peter
    Publication type:
    Article